全文获取类型
收费全文 | 191篇 |
免费 | 9篇 |
国内免费 | 8篇 |
专业分类
儿科学 | 8篇 |
妇产科学 | 4篇 |
基础医学 | 21篇 |
口腔科学 | 1篇 |
临床医学 | 20篇 |
内科学 | 82篇 |
皮肤病学 | 7篇 |
神经病学 | 6篇 |
特种医学 | 18篇 |
外科学 | 12篇 |
综合类 | 2篇 |
预防医学 | 2篇 |
眼科学 | 1篇 |
药学 | 18篇 |
肿瘤学 | 6篇 |
出版年
2021年 | 1篇 |
2020年 | 2篇 |
2019年 | 5篇 |
2018年 | 5篇 |
2017年 | 3篇 |
2016年 | 1篇 |
2015年 | 7篇 |
2014年 | 10篇 |
2013年 | 6篇 |
2012年 | 10篇 |
2011年 | 12篇 |
2010年 | 9篇 |
2009年 | 7篇 |
2008年 | 10篇 |
2007年 | 8篇 |
2006年 | 1篇 |
2005年 | 7篇 |
2004年 | 11篇 |
2003年 | 5篇 |
2002年 | 5篇 |
2001年 | 4篇 |
2000年 | 2篇 |
1999年 | 3篇 |
1998年 | 7篇 |
1997年 | 10篇 |
1996年 | 5篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 6篇 |
1992年 | 3篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1975年 | 5篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1941年 | 1篇 |
排序方式: 共有208条查询结果,搜索用时 15 毫秒
41.
Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
下载免费PDF全文
![点击此处可从《Liver international》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Jordan J. Feld Ira M. Jacobson Mark S. Sulkowski Fred Poordad Fernando Tatsch Jean‐Michel Pawlotsky 《Liver international》2017,37(1):5-18
Over the past two decades, ribavirin has been an integral component of treatment for hepatitis C virus (HCV) infection, where it has been shown to improve the efficacy of (pegylated) interferon. However, because of treatment‐limiting side effects and its additive toxicity with interferon, the search for interferon‐ and ribavirin‐free regimens has been underway. The recent approvals of all‐oral direct acting antivirals (DAAs) have revolutionized the HCV therapeutic landscape, and initially it was expected that the role of ribavirin with DAA regimens would be eliminated. On the contrary, what we have witnessed is that ribavirin retains an important role in the optimal treatment of some subgroups of patients, particularly those that historically have been considered the most difficult to cure. Fortunately, it has also been recognized that the safety profile of ribavirin is improved when co‐administered with all‐oral DAA combinations in the absence of interferon. Despite the antiviral mechanism of action of ribavirin being poorly understood, we now have a range of novel insights into the potential role of ribavirin in all‐oral DAA HCV treatment and greater insight into the antiviral mechanism by which it continues to provide clinical benefit for defined patient groups. 相似文献
42.
Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes 总被引:11,自引:0,他引:11
BACKGROUND: Transfusion-associated graft-versus-host disease (TA-GVHD) may occur in transfusions of blood from HLA-homozygous persons to HLA- heterozygous persons who share a haplotype. STUDY DESIGN AND METHODS: Two mathematical models were developed to calculate the upper and lower limit of the associated risks in various populations using a combination of serology- and DNA sequence-based HLA haplotype frequencies. RESULTS: For nondirected transfusion, the range of the estimated risk in United States whites is 1 of 17,700 to 39,000 (1/6,900-48,500 in Germans; 1/1,600-7,900 in Japanese). The risk in directed donation between parents and children is increased at least 21- fold for US whites, 18-fold for Germans, and 11-fold for Japanese. CONCLUSION: For nondirected transfusions, the estimates of TA-GVHD risk derived in this model are lower than estimates of previously published models, are in better agreement with the clinical experience, and explain in part the observed discrepancy between TA-GVHD incidence in the United States and that in Japan. Most notably for US whites, the relative increase in risk in directed transfusion is larger than previously thought. 相似文献
43.
Hamers F Downs AM Alix J Brunet JB 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》1997,2(5):36-37
In 1996, 24 920 AIDS cases were reported in the WHO European Region, bringing the cumulative total to 185 808 cases including 6969 (4%) paediatric cases (<13 years). For the first time since the start of the epidemic, the annual number of cases reported d 相似文献
44.
Saeed M; Braun SD; Cohan RH; Sussman SK; Illescas FF; Perlmutt LM; Newman GE; Dunnick NR 《Radiology》1987,165(2):345-349
The choice of a contrast agent for pulmonary angiography has important implications for patient comfort, image quality, and perhaps the safety of the procedure, particularly for "high-risk" patients. In a prospective study the nonionic, low-osmolality agent iopamidol eliminated the problem of image degradation due to coughing, and patients showed excellent tolerance for it. However, pressure measurements obtained within 3-5 minutes of injection of iopamidol and diatrizoate sodium meglumine 76% showed no significant difference in the hemodynamic effects of the two contrast agents, either for normotensive or for pulmonary hypertensive patients. Contrary to a common presumption, pulmonary hypertension by itself did not appear to increase the risk of pulmonary angiography. The theoretic presumption of greater hemodynamic stability with low-osmolality contrast agents was not clinically evident in this trial with iopamidol. At present, enhanced patient comfort and improved image quality remain the only confirmed bases for choosing this contrast agent for pulmonary angiography. 相似文献
45.
Eric J. Lawitz Angie Coste Fred Poordad Naim Alkhouri Nicole Loo Bryan J. McColgan Jacqueline M. Tarrant Tuan Nguyen Ling Han Chuhan Chung Adrian S. Ray John G. McHutchison G. Mani Subramanian Robert P. Myers Michael S. Middleton Claude Sirlin Rohit Loomba Edna Nyangau Marc Hellerstein 《Clinical gastroenterology and hepatology》2018,16(12):1983-1991.e3
46.
CJ McIntyre JLY Allen VA Constantinides JE Jackson NS Tolley FF Palazzo 《Annals of the Royal College of Surgeons of England》2015,97(8):598-602
Introduction
Reoperative parathyroidectomy is required when there is persistent or recurrent hyperparathyroidism following the initial surgery (at least 5% of parathyroidectomies nationally). By convention, ‘persistent disease’ is defined as the situation where the patient has not been cured by the first operation. The term ‘recurrent hyperparathyroidism’ is used when the patient was confirmed to be biochemically cured for six months from the first operation but has hyperparathyroidism after this date. Reoperative surgery is associated with higher rates of postoperative complications as well as a greater rate of failure to cure. The aim of our study was to review our departmental experience of reoperative parathyroidectomy, with a view to identify patterns of disease persistence and recurrence.Methods
Using a departmental database, patients were identified who had undergone reoperative parathyroidectomy between 2006 and 2014. All the pre, intra and postoperative information was documented including the operative note so as to record the location of the abnormal parathyroid gland found at reoperation.Results
Almost two-thirds (63%) of patients had negative, equivocal or discordant conventional imaging so secondary investigative tools were required frequently. The majority of abnormal glands were found in eutopic locations. The most common locations for ectopic glands were intrathyroidal, mediastinal and intrathymic. A third (33%) of the patients had multigland disease and over a quarter (28%) had coexisting thyroid disease.Conclusions
Persistent hyperparathyroidism represents a challenging patient subgroup for which access to all radiological modalities and intraoperative parathyroid hormone monitoring are required. Patient selection for reintervention is a key determinant in the reoperation cure rate. 相似文献47.
Alexander J. Thompson Mark S. Sulkowski Jacques Fellay Thomas Urban Ira M. Jacobson Fred Poordad Jonathan McCone Greg W. Galler Robert Reindollar Paul Y. Kwo Bradley Freilich Stefan Zeuzem David M. Vock Keyur Patel Hans L. Tillmann Stephanie Noviello Lisa D. Pedicone Janice K. Albrecht John G. McHutchison 《Gastroenterology》2010,139(1):120-129
48.
Predicting hepatitis C treatment outcomes is of great benefit to patient and clinician. Baseline predictors of response or
failure can set the appropriate expectations for the patient and may aid in decision making about starting therapy. An accurate
assessment of the potential for treatment success involves using rapid and early viral kinetics at weeks 4 and 12. These time
points are useful to set up stopping rules and to provide motivation for the patient and health care provider to continue
when appropriate. Relapse is an unfortunate consequence of therapy in a significant number of patients. Baseline and on-treatment
viral assessments are useful in helping predict and perhaps reduce this phenomenon. 相似文献
49.
50.